Paul Berns is a Managing Director at ARCH Venture Partners. He has held executive leadership roles at several biopharmaceutical companies and has co-founded multiple therapeutics firms.
At firms with a similar stage, sector and check size.
One email when Paul's firm raises a fund, adds a partner or shows new activity.

Raising a pre-seed or seed round? We write $1M to $5M first checks and help founders with distribution. A partner reads every deck.
Send your deckPaul Berns is a Managing Director at ARCH Venture Partners. He has held executive leadership roles at several biopharmaceutical companies and has co-founded multiple therapeutics firms.
Paul Berns invests through Arch Venture Partners, which writes checks of $25K to $30M+ at pre-seed, seed, series a, series b.
A warm intro from a founder Arch Venture Partners backed works best.
Bristol-Myers Squibb (BMS); Vice President, Marketing at BASF Pharmaceuticals/Knoll; President and Chief Executive Officer at Bone Care International; President and Chief Executive Officer at Allos Therapeutics.
Last updated 2026-10-15. Is this you? Ask for a correction.